Improved outcome in central nervous system aspergillosis.
Tattevin
Pierre
P
Le Tulzo
Yves
Y
D000935:Antifungal Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D008297:Male; D020953:Neuroaspergillosis / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D016377:Organ Transplantation / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D014230:Triazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics; D065819:Voriconazole
D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D065819:Voriconazole